Scarica l'app Stockscreener
10.97
0.27%
0.03
Dopo l'orario di chiusura:
10.98
0.010
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$10.94
Aprire:
$10.89
Volume 24 ore:
11.14M
Relative Volume:
1.71
Capitalizzazione di mercato:
$7.73B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
1.9416
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
-3.77%
1M Prestazione:
-1.79%
6M Prestazione:
-9.19%
1 anno Prestazione:
+3.88%
Intervallo 1D:
$10.83
$11.07
Intervallo di 1 settimana:
$10.83
$11.62
Portata 52W:
$8.73
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.97 | 7.73B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
HC Wainwright & Co. Reiterates Buy Rating for Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating on Roivant Sciences stock By Investing.com - Investing.com India
H.C. Wainwright reiterates buy rating on Roivant Sciences stock By Investing.com - Investing.com India
Guggenheim maintains buy rating on Roivant Sciences stock amid DM study - Investing.com India
JPMorgan Maintains Positive Outlook on Roivant Sciences (ROIV) | ROIV Stock News - GuruFocus
Roivant (ROIV) Hosts Investor Webinar on Brepocitinib's Role in Dermatomyositis | ROIV Stock News - GuruFocus
Long Term Trading Analysis for (ROIV) - news.stocktradersdaily.com
Roivant (ROIV) Publishes Promising Phase 1 Results for Inhaled M - GuruFocus
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus By Investing.com - Investing.com South Africa
Roivant Sciences at Goldman Sachs Conference: Strategic Execution Focus - Investing.com Australia
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Yahoo Finance
Major Shareholder Cashes Out Millions in Roivant Sciences Stock - TipRanks
(ROIV) Trading Advice - news.stocktradersdaily.com
Vivek Ramaswamy’s firm wants to buy biotech companies to bet on bitcoin - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $324,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
Roivant Sciences Earnings Call: Balancing Growth and Challenges - MSN
Roivant outlines packed 36-month launch and data cycle with under $5B cash reserve and multi-blockbuster pipeline - MSN
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight - GuruFocus
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st
While Wall Street Naps, These 10 Stocks Run Wild - Insider Monkey
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday - Insider Monkey
Roivant Sciences Ltd (ROIV) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
Roivant Sciences Reports Progress and Financial Results - TipRanks
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates - MSN
IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm – Company AnnouncementFT.com - Financial Times
ROIV Crosses Above Key Moving Average Level - Nasdaq
Roivant Sciences earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
Roivant Sciences Q4 2025 Earnings Call Transcript - MarketBeat
Roivant Sciences (ROIV) Stock Jumps Nearly 5%: What’s Fueling This Biotech Rally? - Daily Chhattisgarh News
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com
Transcript : Roivant Sciences Ltd., Q4 2025 Earnings Call, May 29, 2025 - marketscreener.com
Roivant Sciences Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on April 2, 2024. - marketscreener.com
Roivant Sciences Ltd. Reports Q4 and FY 2025 Financial Results - TradingView
Roivant (ROIV) Reports Decrease in Q4 Revenue but Highlights Strategic Progress | ROIV Stock News - GuruFocus
Roivant Sciences Fiscal Q4 Net Loss Widens, Revenue Falls - marketscreener.com
Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Reports Q4 Revenue $7.6M, vs. FactSet Est of $54.1M - marketscreener.com
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update - Yahoo Finance
H.C. Wainwright maintains $18 target on Roivant Sciences stock - Investing.com Australia
Roivant Sciences (NASDAQ:ROIV) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock - MSN
Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com
Roivant Sciences's Earnings Outlook - Nasdaq
What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings - GuruFocus
H.C. Wainwright maintains $18 target on Roivant Sciences stock By Investing.com - Investing.com India
Roivant Sciences (ROIV) Receives Reiterated Buy Rating from HC W - GuruFocus
Ameriprise Financial Inc. Lowers Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - Defense World
(ROIV) Investment Analysis and Advice - news.stocktradersdaily.com
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & COO |
Jun 20 '25 |
Sale |
11.45 |
100,000 |
1,145,000 |
1,462,223 |
| Ramaswamy Vivek | 10% Owner |
Jun 20 '25 |
Sale |
11.46 |
577,007 |
6,612,500 |
37,284,108 |
| Ramaswamy Vivek | 10% Owner |
Jun 18 '25 |
Sale |
11.45 |
565,266 |
6,472,296 |
37,861,115 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):